Highlights Roche Holding AG

Stocks

ROP

CH1499059983

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:33 10/07/2026 BST			5-day change	1st Jan Change
336.60 ^CHF	+0.33%		-1.17%	+2.56%

07-09	Roche's Tuberculosis Test Receives CE Mark	MT
07-08	ABB Robotics Partners with Roche Diagnostics	MT

Highlights

07-09	Roche's Tuberculosis Test Receives CE Mark	MT
07-08	ABB Robotics Partners with Roche Diagnostics	MT
07-07	Roche Presents New Data in Alzheimer?S Disease Portfolio At Aaic 2026	CI
07-02	Roche Reports Positive Results from Phase Iii Krascendo 1 Study Evaluating Divarasib Against Approved Kras G12c Inhibitors in Previously Treated Kras G12c Non-Small Cell Lung Cancer	CI
06-30	Roche Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Enspryng for Thyroid Eye Disease	CI
06-30	Roche Receives US Priority Review Status for Thyroid Eye Disease Treatment	MT
06-29	Excalipoint Therapeutics And Roches Announce Clinical Trial Collaboration To Evaluate EXP011 In DLL3-Expressing Solid Tumors	CI
06-29	Roche Announces Launch Of AXELIOS 1 Sequencing Platform	CI
06-29	Switzerland's Roche Introduces New Sequencing Platform	MT
06-24	Roche Holding AG Announces FDA Grants Priority Review Status to its Atezolizumab for Treatment of Certain Type of Stage III Colorectal Cancer	CI
06-18	Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma	CI
06-18	Roche Wins US FDA Nod for Lymphoma Drug Combo	MT
06-17	FDA approves first generic version of Roche's flu drug	RE
06-12	Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer	CI
06-11	Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer	CI
06-11	Roche's Tecentriq, Chemotherapy Combo Gets US FDA Priority Review for Colon Cancer	MT
06-11	Roche Announces IVDR Approval For VENTANA MMR RxDx Panel Companion Diagnostic Across Multiple Cancer Types And Therapies	CI
06-08	Roche Holding AG And Nurix Therapeutics, Inc. Announce Global Collaboration To Co-Develop And Co-Commercialise Potential Best-In-Class BTK Degrader Bexobrutideg Across Malignant Haematology, Immunology And Neurology	CI
06-08	Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics	RE
06-08	Roche enters $2 billion cancer drug agreement with Nurix Therapeutics	RE
06-08	Roche, Nurix Therapeutics to Develop, Commercialize BTK Degrader Bexobrutideg	MT
06-05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
06-02	Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi in Combination with Palbociclib and Fulvestrant	CI
06-02	Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer	CI
06-02	Roche Wins US FDA's Priority Review for Breast Cancer Treatment Giredestrant	MT